Original Article

Long non-coding RNA LINC00460 promotes head and neck squamous cell carcinoma cell progression by sponging miR-612 to up-regulate AKT2

Xiaoxing Xie, Gaoyun Xiong, Qingliang Wang, Yanping Ge, Xiaoying Cui

1Department of Otolaryngology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, China; 2Departement of Anesthesiology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China

Received May 14, 2019; Accepted June 11, 2019; Epub October 15, 2019; Published October 30, 2019

Abstract: LncRNAs (long noncoding RNAs) have been shown to be potentially critical regulators in head and neck squamous cell carcinoma (HNSCC). LncRNA LINC00460 (long intergenic non-protein coding RNA 460), an “oncogene”, regulates progression of various tumors. However, the tumorigenic mechanism of LINC00460 on HNSCC is yet to be investigated. In the current study, we discovered that LINC00460 was relatively up-regulated in both HNSCC cancer tissues and cell lines, and predicted a poor prognosis in HNSCC patients. Gain- and loss-of-functional studies established that over-expression of LINC00460 promoted cell proliferation, invasion and migration of HNSCC cells in vitro, while the promotion abilities were suppressed via knockdown of LINC00460. Our results identified miR-612 as a novel target of LINC00460, whose expression suggested a negative correlation with LINC00460 in HNSCC tissues and cell lines. LINC00460 increased the expression of serine/threonine kinase AKT2 via sponging miR-612. Rescue experiments indicated that LINC00460 could promote HNSCC progression partially through inhibition of miR-612. Subcutaneous xenotransplanted tumor model confirmed that interference of LINC00460 suppressed in vivo tumorigenic ability of HNSCC via down-regulation of AKT2. In conclusion, our findings clarified the biologic significance of LINC00460/miR-612/AKT2 axis in HNSCC progression and provided novel evidence that LINC00460 may be a new potential therapeutic target for HNSCC.

Keywords: LINC00460, miR-612, AKT2, HNSCC, progression

Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks the sixth most common cancer worldwide [1]. By the means of TNM (tumor-node-metastasis) classification of malignant tumors, HNSCC is assigned with stage I, II, III and IV [2]. Although the therapeutical treatment for HNSCC has been progressed tremendously in the last several decades, the overall survival rate for HNSCC patients has not been improved due to local recurrence and distant metastasis [3]. Therefore, it is of great clinical significance to investigate the genetic and epigenetic molecular alterations in HNSCC to improve the survival rate of patients.

LncRNAs (long noncoding RNAs), with more than 200 nucleotides in length, have been considered as transcriptional or post-transcriptional regulators of gene expression [4] and participate in various physiological and pathological processes [5, 6]. According to the critical regulation on cell proliferation, migration and invasion [7], IncRNAs are recently acquired great attention in cancer research. LINC00460 (long intergenic non-protein coding RNA 460), as an “oncogene”, has been reported to play an important role in nasopharyngeal cancer [8], esophageal squamous cell carcinoma [9], and lung cancer [10]. Recently, research has shown that LINC00460 might be a novel prognosis predictor of patients with HNSCC [11]. However, the mechanism of LINC00460 in the progression process of HNSCC is still under investigation.

Studies have investigated the application of miRNAs as diagnostic/prognostic biomarkers or potential therapeutic targets for improve-
ment of HNSCC [12]. Moreover, considering that IncRNAs often act as a miRNA sponges or ceRNAs (competitive endogenous RNAs) to participate in various biological processes [13], it is an urgent need to discover the target for LINC00460 in HNSCC. MiR-612 plays an important role in liver cancer [14], hepatocellular carcinoma [15] and melanoma [16] as a tumor suppressor. MiR-612 was reported to be involved in the development and metastasis of esophageal squamous cell carcinoma [17]. In addition, several studies have shown that miR-612 could bind to AKT2 [18, 19], which is involved in the promotion of the development of HNSCC [20]. Therefore, we evaluated the hypothesis that LINC00460, together with the downstream regulators miR-612/AKT2, may be involved in regulation of HNSCC progression.

We not only detect the impact of LINC00460 on tumor proliferation, migration and invasion of HNSCC, but also explore the underlying mechanism. The meaningful results would provide a reference for development of new therapies for HNSCC.

## Materials and methods

### Patients and tumor tissues collection

60 HNSCC patients, diagnosed via pathology examination and confirmed with imaging modalities, were recruited in this study. The clinicopathological characteristics of the patients were shown in Table 1. The present study was approved by Tongde Hospital of Zhejiang Province, and all the patients signed written informed consent. The HNSCC tissues and adjacent normal tissues were collected from the patients.

### In situ hybridization

5 μm sections made from HNSCC and adjacent normal tissues were firstly fixed with 10% formalin, and embedded in paraffin. Following by dewaxing and rehydrating, the tissue sections were then digested with 20 µg/mL proteinase K for 30 minutes. 4% paraformaldehyde-fixed samples were hybridized overnight with 8 ng/μL specific antisense oligonucleotide DNA probe 5’-GGCTGAGGCATTTCTAACAGGGCTGGAGGA-3’ synthesized by Invitrogen (Carlsbad, CA, USA) at 55°C. The samples were then incubated with HRP (horseradish peroxidase, Sigma Aldrich, St. Louis, MO, USA) at 4°C for 30 minutes. Hybridization signals were amplified with diaminobenzidine (DAB, Sigma Aldrich), and the images were taken by fluorescent microscope (DP12 SZX7, Olympus Inc., Japan).

### Cell culture and transfection

HNSCC cell lines (HSC3, Fadu and SAS) and normal immortal keratinocyte cell line from adult human skin (HACA), purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA), were cultured in Dulbecco modified Eagle medium (DMEM; Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum (FBS, Gibco, MA, USA) with additional streptomycin (100 μg/ml) and penicillin (100 U/ml). 37°C constant temperature incubator with 5% CO₂ was utilized to incubating cells.

For the over-expression of LINC00460, full-length of LINC00460 was ampliﬁed and cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). Fadu or SAS cells were seeded at 4×10⁵ cells per well in 12-well plates and then transfected with pcDNA3.1-LINC00460 or the negative (pcDNA3.1-NC) via Lipofectamine 2000 (Invitrogen). For the knock down of LINC00460, shRNAs (1#: 5’-GCTGAGGCGATCTAAGCCTG-3’ and 2#: 5’-GCTGAGGCGATCTAAGCCTG-3’) were inserted into pLKO.1 (Biosettia, San Diego, CA, USA). 4×10⁵/well HEK-293T cells were cotransfected with pLKO-1# LINC00460 (sh-LINC00-
460#1), pLKO-2# LINC00460 (sh-LINC00460-
#2, sh-LINC00460) or pLKO Scramble (sh-NC)
with psPAX2 and pMD2.G via Lipofectamine
2000. Two days after transfection, lentiviruses
containing released lentiviral vectors were har-
vested. Fadu or SAS cells were infected with sh-
LINC004601#, sh-LINC004602# or sh-NC len-
tiviruses in the presence of ViraPower™ Pa-
ckaging Mix (Thermo Fisher, Waltham, MA,
USA) and 8 mg/mL polybrene. With 5 μg/mL
puromycin (Sigma Aldrich, St. Louis, MO, USA)
treatment for one week, the stable cell lines
were obtained.

MiR-612 mimics, inhibitor and the negative
controls (miR-NC, NC inh) were synthesized by
GenePharma (Suzhou, China). Fadu or SAS
cells were transfected with miR-612 mimics/
inhibitor (40 nM) or their NC via Lipofectamine
2000.

Cell proliferation

1×10^3 Fadu or SAS cells per well were seeded
in s in 96-well plates, and cultured as before for
5 days. Cells were washed with PBS after the
medium was removed, and then incubated with
10 μL CCK8 (cell counting kit-8) reagent (Be-
yotime, Shanghai, China) at 37°C for 2 hours.
The cell viabilities were calculated via detection
of absorbance at 450 nm in 24, 48, 72 and 96
hours after the treatment. For the colony for-
modation assay, 1×10^3 Fadu or SAS cells per well
were plated in six-well plate, and cultured as
before for 14 days. The colonies were stained
by 1% crystal violet-2% ethanol suspended in
PBS (Beyotime), counted and photographed
under light microscope (Olympus, Tokyo, Ja-
pan).

Transwell assay

For cell invasion, 2×10^4 Fadu or SAS cells, sus-
pending in 200 μL DMEM medium without FBS,
were plated into the upper wells of chamber
(BD Biosciences, Bedford, MA, USA) per well
with the Matrigel-coated membrane (BD Bio-
sciences). 500 μL DMEM medium supplement-
ed with 10% FBS were added to the lower wells
of chambers. 24 hours later, invasive cells at
the bottom of chambers were fixed in 100% methanol for 30 minutes, washed with PBS and
then stained with 0.1% crystal violet for 1 hour.
Stained cells were imaged and counted under
microscope. For cell migration experiment, the
upper chambers were not precoated with Ma-
trigel, and then subjected to the protocol as cell
invasion assay.

Fluorescence in situ hybridization (FISH)

Fadu or SAS cells were firstly fixed in 4% formal-
dehyde solution for 15 minutes, and then incu-
bated with 0.1% Triton X-100 for another 10
minutes. Fluorescence-conjugated LINC00460
probes (Invitrogen) were hybridized at 37°C
with cells in the dark for 5 hours. The cells were
then photographed via laser scanning confocal
microscopy (Carl Zeiss, Jena, Germany).

Dual luciferase reporter assay

Sequences of wildtype or mutant 3’-UTR of
LINC00460 or AKT2 were synthesized and then
subcloned into pmirGLO luciferase reporter
vector (Promega, Madison, Wisconsin, USA).
3×10^4 HEK-293T cells per well were seeded in
24-well plates and co-transfected miR-612
mimic or negative control (miR-NC) with pmir-
GLO-wt-LINC00460, pmirGLO-mut-LINC00460,
pmirGLO-wt-AKT2 or pmirGLO-mut-AKT2 via
Lipofectamine 2000. 48 hours after transfec-
tion, the luciferase activities were performed
with the Lucifer Reporter Assay System (Pro-
mega) and normalized to Renilla luciferase
activity.

RNA immunoprecipitation (RIP)

Fadu or SAS cells at 80-90% confluency were
collected and lysate in RIP lysis buffer (EZ-
Magna RIP kit; Millipore, Billerica, MA, USA),
and then 100 μL samples were incubated with
protein G Sepharose beads (GE Healthcare,
Eindhoven, The Netherlands) coated with anti-
AGO2 antibody (Abcam, Cambridge, MA, USA)
at 4°C overnight, and anti-IgG antibody was
used as the negative control for the RIP proce-
dure, while anti-SNRNP70 was used as positive
control. The samples were incubated with
Proteinase K to digest the protein and then
immunoprecipitated RNA was isolated for qRT-
PCR as mentioned below to demonstrate the
presence of the binding targets using respec-
tive primers.

qRT-PCR

Total RNAs from HNSCC tissues or cell lines
were isolated with Trizol (Invitrogen), miRNAs
LncRNA LINC00460 was induced in both HNSCC tumor tissues and cell lines

We firstly detect the expression level of LncRNA LINC00460 in HNSCC to explore the effect of LINC00460 on HNSCC progression. qRT-PCR analysis demonstrated that LINC00460 was significantly upregulated in HNSCC tumor tissues (HNSCC) compared to the adjacent nor-
LINC00460/miR-612/AKT2 in head and neck squamous cell carcinoma

Figure 1. LncRNA LINC00460 was induced in both HNSCC tumor tissues and cell lines. A. The expression of LncRNA LINC00460 in HNSCC tissues and adjacent normal tissues was detected by qRT-PCR (N=60). ***represents tumor vs. adjacent normal tissues, P < 0.001. B. OS analysis was performed in HNSCC patients with high LINC00460 expression and low levels of LINC00460. C. The expression of LINC00460 in HNSCC cell lines (HSC3, Fadu and SAS) and normal immortal keratinocyte cell line from adult human skin (HACA) was detected by qRT-PCR. **, ***represents HNSCC cell lines vs. HACA, P < 0.01, P < 0.001. D. In situ hybridization (ISH) analysis was conducted to analyze the LINC00460 expression in HNSCC tissues.

Figure 2. The effects of LINC00460 on HNSCC cell proliferation, migration and invasion. A. In vitro transfection of Fadu and SAS cell lines with pcDNA3.1-LINC00460 for the over-expression of LINC00460, which were confirmed by qRT-PCR in Figure 2A. Then CCK8 (Figure 2B) and colony formation (Figure 2C) assays revealed the promotion ability of LINC00460 over-expression on cell proliferation of Fadu and SAS cells. Furthermore, transwell assay indicated the promotion ability of LINC00460 over-expression on cell migration and invasion of Fadu and SAS cells (Figure 2D). Expression of genes involved in cell progression was also detected via qRT-PCR and western blot analysis. The results showed that both mRNA (Figure 2E) and protein (Figure 2F) expression of Cyclin D and N-cadherin were increased by LINC00460 over-expression, whereas the expression of p21 and E-cadherin were decreased by LINC00460 over-expression (Figure 2E and 2F).

In addition, loss-of-functional assays were also conducted. Similarly, Fadu and SAS cell lines transfected with sh-LINC00460#1 or sh-LINC00460#2 for the knock down of LINC00460, and the knockdown efficiency was confirmed by qRT-PCR (Figure 3A). sh-LINC00460#2 showed a better knockdown efficiency and was chosen for the following experiments, and named as sh-LINC00460. CCK8 (Figure 3B) and colony formation (Figure 3C) assays revealed the suppression ability of LINC00460 knockdown on the cell proliferation of Fadu and SAS cells. Transwell assay indicated the suppression ability of LINC00460 knockdown on cell migration and invasion of Fadu and SAS cells. (Figure 3D).
and SAS cells (Figure 3D). In contrary to the effect of LINCO0460 over-expression on genes expression, both mRNA (Figure 3E) and protein (Figure 3F) expression of Cyclin D and N-cadherin were decreased by sh-LINC00460, while the expression of p21 and E-cadherin were increased by sh-LINC00460 (Figure 3E and 3F). All these results further suggested that LINCO0460 may account for the malignant phenotypes of HNSCC.

LINCO0460 directly bound to miR-612 and inhibited its expression

In order to detect the subcellular localization of LINCO0460, nuclear/cytoplasmic extract isolation of Fadu and SAS cells were conducted. qRT-PCR analysis suggested that LINCO0460 was mainly localized in cytoplasm (Figure 4A). Moreover, the results from fluorescent in situ hybridization (FISH) detected by microscope further indicated the cytoplasm location of LINCO0460 (Figure 4B). LINCO0460 was predicted to bind with miR-612 via miRDB (http://www.mirdb.org/) (Figure 4C), and dual luciferase reporter assay revealed that miR-612 mimics decreased the luciferase activity of pmirGLO-wt-LINC00460, while did not affect the luciferase activity of pmirGLO-mut-LINC00460 (Figure 4C). RNA immunoprecipitation (RIP) assay further confirmed the direct binding between LINCO0460 and miR-612, as shown by an enrichment of LINCO0460 and miR-612 with AGO2 antibody in both Fadu and SAS cells (Figure 4D). The expression of miR-612 was decreased by LINCO0460 over-expression and increased by LINCO0460 knockdown (Figure 4E). Collectively, these results indicated that LINCO0460 could directly bind to miR-612 and inhibited its expression. A down-regulation of miR-612 was found in HNSCC tumor tissues (Figure 4F). Bivariate correlation analysis showed that expression of miR-612 was negatively correlated with LINCO0460 in HNSCC (Figure 4G).

AKT2 was a direct target of miR-612

Similarly, AKT2 was predicted as miR-612 binding target via Targetscan, and confirmed by luciferase reporter assay as demonstrated in Figure 5A. miR-612 mimics decreased the luciferase activity of pmirGLO-wt-AKT2, while it had no effect on the luciferase activity of pmirGLO-mut-AKT2. Then Fadu and SAS cells were transfected with miR-612 mimics or inhibitor, and the transfection efficiency was confirmed via qRT-PCR (Figure 5B). The results showed that miR-612 mimics decreased mRNA (Figure 5B) and protein (Figure 5C) expression of AKT2, while miR-612 inhibitor increased mRNA (Figure 5B) and protein (Figure 5C) expression of AKT2. Interestingly, phosphorylation of AKT2 (p-AKT2) was also decreased by miR-612 mimics and increased by miR-612 inhibitor (Figure 5C), suggesting the inactivation of AKT2 signaling pathway by miR-612. Consistent with LINCO0460 expression in HNSCC tissues, mRNA expression of AKT2 was also up-regulated in HNSCC tissues (Figure 5D). Bivariate correlation analysis showed that expression of miR-612 was negative correlated with AKT2 in HNSCC (Figure 5E). The up-regulation of AKT2 in HNSCC tissues was also confirmed by western blot analysis (Figure 5F). In summary, these results suggested that AKT2 was a direct target of miR-612.

LINCO0460 induced HNSCC progression via sponging miR-612

To test whether the promotion ability of LINCO0460 on HNSCC progression was partially
through binding with miR-612, Fadu cells were cotransfected with sh-LINC00406 and miR-612 inhibitor. CCK8 (Figure 6A) and colony formation (Figure 6B) assays showed that the inhibition of cell proliferation by sh-LINC00460 was promoted by additional transfection with miR-612 inhibitor. Repression of miR-612 via miR-612 inhibitor reversed the suppression abilities of sh-LINC00460 on cell migration and invasion of Fadu (Figure 6C). The decreased mRNA (Figure 6D) and protein (Figure 6E) expression of AKT2, Cyclin D and N-cadherin, as well as the increased mRNA (Figure 6D) and protein (Figure 6E) expression of p21 and E-cadherin, were reversed by additional transfection with miR-612 inhibitor. Taken together,
these results indicated that LINC00460 functioned as miR-612 sponge to promote cell progression of HNSCC. LINC00460 knockdown inhibited in vivo HNSCC tumor growth

In order to explore the clinical application of LINC00460 on HNSCC, we inoculated Fadu cells transfected with sh-LINC00460 or the scrambled shRNA into nude mice. The down-regulation efficiency of LINC00460 was confirmed by qRT-PCR in Figure 7A. Results showed that the intratumoral injection of lentiviral vector with LINC00460 knockdown inhibited tumor growth, wherein the tumor volume and weight were dramatically decreased compared to that...
LINC00460/miR-612/AKT2 in head and neck squamous cell carcinoma

of scramble (P < 0.001) (Figure 7B). Moreover, full specimen staining with immunohistochemistry revealed that the xenograft tumor tissues injected with sh-LINC00460 reduced the expression of N-cadherin and Ki67 (Figure 7C). The down-regulation of AKT2 and p-AKT2 (Figure 7D) in tumors via LINC00460 knockdown were confirmed by western blot. These results suggest that LINC00460 knockdown suppressed xenograft tumor growth through the regulation of AKT2.

Discussion

LncRNAs function as a promoter or inhibitor of cancer-critical genes of HNSCC, and involved in regulation of diverse cellular processes [21]. Increasing evidence reveals that LINC00460, located at chromosome 13q33.2 [22], plays a vital role in carcinogenesis and progression of various tumors. One of the major findings of the present study is that elevated expression of LINC00460, occurred in HNSCC tissues, was
LINCO0460/miR-612/AKT2 in head and neck squamous cell carcinoma

Figure 5. AKT2 was a direct target of miR-612. A. The predicted binding site of miR-612 in AKT2, as well as the effect of miR-612 mimics on luciferase activity of reporter gene with wild-type or mutant AKT2 were detected by luciferase reporter assay. ***Represents miR-612 mimics vs. miR NC, P < 0.001. B. Transfection efficiency of miR-612 mimics or inhibitor, as well as the influence of miR-612 mimics or inhibitor on mRNA expression of AKT2 in Fadu and SAS cells was detected by qRT-PCR. **, ***Represents miR-612 mimics vs. miR NC or miR-612 inh vs. NC inh, P < 0.01, P < 0.001. C. The influence of miR-612 mimics or inhibitor on protein expression of AKT2 and p-AKT2 in Fadu and SAS cells were detected by western blot. **, ***Represents miR-612 mimics vs. miR NC or miR-612 inh vs. NC inh, P < 0.01, P < 0.001. D. The mRNA expression of AKT2 in HNSCC tissues and adjacent normal tissues was detected by qRT-PCR (N = 60). ***Represents tumor vs. adjacent normal tissues, P < 0.001. E. Negative correlation between AKT2 and miR-612 in HNSCC tissues was analyzed. F. Protein expression of AKT2 in HNSCC tissues and adjacent normal tissues was detected by western blot. *Represents tumor vs. adjacent normal tissues, P < 0.05.

tightly associated with some clinical parameters and predicted a poor prognosis in HNSCC patients. In line with Cao et al. [11], elevated expression of LINCO0460 was associated with poor OS of HNSCC patients with more frequently occurred in patients with T3+T4 (primary tumor stage), III+IV (clinical stage) and lymph node metastasis, suggesting that LINCO0460 might be a poor prognosis indicator for HNSCC. However, due to the small sample size of our
current clinical analysis (N = 60), a larger patient cohort is needed to strengthen the clinical significance of LINC00460 in HNSCC patients in the future.

In line with the clinical results, in vitro gain- and loss-of function assays for the first time showed that over-expression of LINC00460 not only promoted cell proliferation, but also induced...
cell invasion and migration of HNSCC cells, while LINCO0460 knockdown reversed the effect on HNSCC progression. Moreover, in vivo subcutaneous xenotransplanted tumor model revealed that interference of LINCO0460 suppressed in vivo tumorigenic ability of HNSCC, indicating that LINCO0460 is also a potential therapeutic target in HNSCC.

Since the “oncogene” function of LINCO0460 on HNSCC has been found, the underlying mechanism remains to be clarified. To regulate cell progression, Cyclin D1, p21, E-cadherin and N-cadherin were found to be functional targets of LINCO0460 in HNSCC. Generally, Cyclin D1 promoted G1-to-S phase transition during cell cycle [23], and over-expression of Cyclin D1 was significantly correlated with poor prognosis for HNSCC [24, 25]. Down-regulating Cyclin D1 suppressed the malignant phenotype of HNSCC [26]. Moreover, as a cyclin-dependent kinases inhibitors, p21 suppressed cell growth as an antitumor agent [27], and the expression of p21 was significantly correlated with an increased prognosis of oral squamous cell carcinomas [28]. Down-regulation of Cyclin D1 and up-regulation of p21 were associated with inhibition of HNSCC cell proliferation, therefore inhibition of cell progression [29]. The results in the present study showed that LINCO0460 increased the expression of Cyclin D1 and decreased the expression of p21, while LINCO0460 knockdown decreased the expression of Cyclin D1 and increased the expression of p21. Moreover, in addition to the regulation of cell cycle, Cyclin D and p21 are also involved in regulation of cancer cell migration and invasion. TGF β-mediated Cyclin D1 and p21 results in increased cancer migration and invasion and inhibition of these two cell cycle regulators significantly reduces both tumor formation and local tumor invasion [30]. Therefore, Cyclin D1 and p21 may also be involved in regulation of HNSCC migration and invasion.

Epithelial to mesenchymal transition (EMT), essential for the development of metastasis, contributes to the unfavorable prognosis in cancer [10]. Decrease of E-cadherin accompanied by increase of N-cadherin is associated with positive lymph nodes and metastasis in HNSCC [31]. TNF receptor-associated factor 6 (TRAF6) knockdown elevated E-cadherin and down-regulated N-cadherin to inhibit the migration and invasion abilities of HNSCC [32]. The results in the present study showed that LINCO0460 increased expression of N-cadherin and decreased expression of E-cadherin, while LINCO0460 knockdown decreased N-cadherin and increased E-cadherin, showing the anti-

Figure 7. LINCO0460 knockdown inhibited in vivo HNSCC tumor growth. A. Transfection efficiency of sh-LINCO0460 in xenograft tumor mice was detected by qRT-PCR. ** represents sh-LINCO0460 vs. sh-NC, P < 0.01. B. The effect of sh-LINCO0460 on tumor growth in xenograft tumor mice was shown. The tumor volume and weight were calculated. *** Represents sh-LINCO0460 vs. sh-NC, P < 0.001. C. Immunohistochemistry staining was used to determine expression of N-cadherin and Ki-67 affected by sh-LINCO0460. Black bar: 50 μm. D. The effect of sh-LINCO0460 on protein expression of AKT2 and p-AKT2 in xenograft tumor mice was determined by western-blot. *** Represents sh-LINCO0460 vs. sh-NC, P < 0.001.
migration and anti-invasion abilities of LINC00460 knockdown in HNSCC. Moreover, EMT also participates in mediation of cancer stemness. LncRNA PVT1 induced EMT and promoted stemness properties of HNSCC for the metastasis [10]. Considering that LINC00460 is associated with EMT in lung cancer [10] and non-small cell lung cancer [33], the effect of LINC00460 on stemness properties of HNSCC will be explored in the future studies.

As well known, biological function of lncRNAs depends on the miRNAs and proteins they bind. There are no reported targets for LINC00460 in HNSCC before. The present study revealed a new miRNA target for LINC00460, miR-162, a common “oncogene” which was shown to be involved in the pathogenesis of various tumors. MiR-612/AKT2 axis negatively regulates progression of colorectal cancer [18] and glioblastoma [19]. The results of this study for the first time indicated that LINC00460 could promote HNSCC progression by sponging miR-612 to up-regulate AKT2. Serine/threonine kinase AKT plays an important role in the regulation of cell proliferation and survival, where AKT activation is related to tumor development and poor prognosis [34]. Decreased phosphorylation of AKT showed anti-tumor activity in HNSCC [35]. Moreover, AKT2 acts as a metastasis promoter, with its over-expression increasing the incidence of metastases [36] while its knockdown suppressing cell migration and EMT [37]. In vitro and in vivo loss-of-function assays showed that LINC00460 knockdown decreased the expression of AKT2 and p-AKT2, thus suppressing cell progression of HNSCC. However, AKT/NF-κB signaling responsible for inflammatory regulation in tumors is yet to be investigated in the present study.

Conclusion

In summary, our results demonstrated that IncRNA LINC00460, as an “oncogene”, whose knockdown inhibited cell proliferation, migration and invasion of HNSCC cells via sponging miR-612 and targeting AKT2. This finding illuminated the relation between LINC00460/miR-612/AKT2 regulatory axis and HNSCC progression, suggesting potential application of LINC00460 in treatment for the disease.

Acknowledgements

All data generated or analyzed during this study are included in this published article. XXX and GYX conceived and designed the experiments, QLW analyzed and interpreted the results of the experiments, YPG and XYC performed the experiments. All procedures performed in studies involving human participants were in accordance with the standards upheld by the Ethics Committee of Tongde Hospital of Zhejiang Province and with those of the 1964 Helsinki Declaration and its later amendments for ethical research involving human subjects. (XMSC2018146). All animal experiments were approved by the Ethics Committee of Tongde Hospital of Zhejiang Province for the use of animals and conducted in accordance with the National Institutes of Health Laboratory Animal Care and Use Guidelines. (XMSC2019037).

Disclosure of conflict of interest

None.

Address correspondence to: Gaoyun Xiong, Department of Otolaryngology, Tongde Hospital of Zhejiang Province, 234 Gu cui Road, Hangzhou 310012, Zhejiang, China. Tel: 86+ 0571-89972177; E-mail: GaoyunXionghjk@163.com

References

sponging miR-149-5p to up-regulate IL6. Gene 2018; 639: 77-84.


